Samuels M H, Schuff K G, Carlson N E, Carello P, Janowsky J S
Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
J Clin Endocrinol Metab. 2008 May;93(5):1730-6. doi: 10.1210/jc.2007-1957. Epub 2008 Feb 19.
Our objective was to determine whether subclinical thyrotoxicosis alters health status, mood, and/or cognitive function.
This was a double-blinded, randomized, cross-over study of usual dose l-T(4) (euthyroid arm) vs. higher dose l-T(4) (subclinical thyrotoxicosis arm) in hypothyroid subjects.
A total of 33 hypothyroid subjects receiving l-T(4) were included in the study.
Subjects underwent measurements of health status, mood, and cognition: Short Form 36 (SF-36); Profile of Mood States (POMS); and tests of declarative memory (Paragraph Recall, Complex Figure), working memory (N-Back, Subject Ordered Pointing, and Digit Span Backwards), and motor learning (Pursuit Rotor). These were repeated after 12 wk on each of the study arms.
Mean TSH levels decreased from 2.15 to 0.17 mU/liter on the subclinical thyrotoxicosis arm (P < 0.0001), with normal mean free T(4) and free T(3) levels. The SF-36 physical component summary and general health subscale were slightly worse during the subclinical thyrotoxicosis arm, whereas the mental health subscale was marginally improved. The POMS confusion, depression, and tension subscales were improved during the subclinical thyrotoxicosis arm. Motor learning was better during the subclinical thyrotoxicosis arm, whereas declarative and working memory measures did not change. This improvement was related to changes in the SF-36 physical component summary and POMS tension subscales and free T(3) levels.
We found slightly impaired physical health status but improvements in measures of mental health and mood in l-T(4) treated hypothyroid subjects when subclinical thyrotoxicosis was induced in a blinded, randomized fashion. Motor learning was also improved. These findings suggest that thyroid hormone directly affects brain areas responsible for affect and motor function.
我们的目的是确定亚临床甲状腺毒症是否会改变健康状况、情绪和/或认知功能。
这是一项针对甲状腺功能减退受试者的双盲、随机、交叉研究,比较常规剂量左甲状腺素(甲状腺功能正常组)与高剂量左甲状腺素(亚临床甲状腺毒症组)。
共有33名接受左甲状腺素治疗的甲状腺功能减退受试者纳入本研究。
受试者接受健康状况、情绪和认知测量:简明健康状况调查量表(SF-36);情绪状态剖面图(POMS);以及陈述性记忆测试(段落回忆、复杂图形)、工作记忆测试(n-back、主题有序指向和数字广度倒序)和运动学习测试(追踪转子)。在每个研究组治疗12周后重复这些测量。
亚临床甲状腺毒症组的平均促甲状腺激素(TSH)水平从2.15 mU/升降至0.17 mU/升(P<0.0001),平均游离甲状腺素(FT4)和游离三碘甲状腺原氨酸(FT3)水平正常。在亚临床甲状腺毒症组期间,SF-36身体成分总结和一般健康子量表略差,而心理健康子量表略有改善。在亚临床甲状腺毒症组期间,POMS困惑、抑郁和紧张子量表有所改善。亚临床甲状腺毒症组的运动学习更好,而陈述性和工作记忆测量没有变化。这种改善与SF-36身体成分总结、POMS紧张子量表和FT3水平的变化有关。
我们发现,在一项双盲、随机诱导亚临床甲状腺毒症的研究中,接受左甲状腺素治疗的甲状腺功能减退受试者的身体健康状况略有受损,但心理健康和情绪测量指标有所改善。运动学习也得到了改善。这些发现表明甲状腺激素直接影响负责情感和运动功能的脑区。